CDK4 and neoplasm: Cyclin-dependent kinase 4/6 (CDK4/6) is a downstream target of activated/phosphorylated ERK and there is evidence for anti-tumor activity of the dual ERK and CDK4/6 inhibition, using ulixertinib and palbociclib, respectively (Table 1) [50,51] (Figure 1).